Navigation Links
Fourth IMPAKT Breast Cancer Conference
Date:4/25/2012

but many
  • Mucin-1 protein and mRNA expression in breast cancer patients treated with neoadjuvant chemotherapy
  • Independent blinded validation of the genomic index of Sensitivity to Endocrine Therapy (SET)
  • The role of AP-1 in endocrine-resistant breast cancer
  • Advances in breast cancer research help choose the right treatment for the right patient
  • Gene modules and pathological complete response to neoadjuvant chemotherapy in breast cancer: a pooled analysis
  • Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically-defined Luminal A breast cancer
  • Translational studies within the TAMRAD randomized GINECO trial: Evidence for TORC1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer
  • Breast cancer in young women is a biologically unique disease that requires customized management strategies

    Highlights on:

    • Challenges, clinical perspectives and implications for biomarker and drug development
    • Making personalized medicine a reality for breast cancer patients: how to speed up the path for reimbursement
    • Intratumor heterogeneity: a challenge for personalized medicine? Can next generation sequencing help solve the problem?
    • Towards a further segmentation of triple negative breast cancer?
    • Can gene signatures become a standard procedure for daily practice? What's new to predict outcome and drug sensitivity?

    Press conference

    Thursday, 3 May 2012, 11:00-12:00 (CEST)

    Hosts:

    Martine Piccart, Jules Bordet Institute, Head of Chemotherapy Unit, Brussels, Belgium, IMPAKT Co-Founder

    Fabrice Andr, Institut de Cancrologie Gustave Roussy, Breast cancer Unit, Department of Medical Oncology, Villejuif, France, IMPAKT2012 Scientific Chair

    Sherene Loi, Institute Jules Bordet, Breast International Group (BIG), Brussels, Belgium, IMPAKT2012 Executive Chair

    Th
    '/>"/>


  • Contact: Vanessa Pavinato
    media@esmo.org
    European Society for Medical Oncology
    Source:Eurekalert

    Page: 1 2 3

    Related biology news :

    1. Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008
    2. BIO-key(R) Announces Fourth Quarter and 2008 Year-End Earnings Release and Conference Call Schedule
    3. Aware, Inc. Reports Fourth Quarter and 2008 Financial Results
    4. BIO-key(R) Reports Profitability for Fourth Quarter and Full Year 2008
    5. Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results
    6. BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability
    7. MiMedx Group, Inc. Announces Release Date for 2010 Fourth Quarter and Full Year Results
    8. AACR hosts Fourth Annual Science of Cancer Health Disparities Conference
    9. Modern genetics answers age-old question on Garrods fourth inborn error of metabolism
    10. Aware, Inc. Reports Fourth Quarter and 2011 Financial Results
    11. IMPAKT -- Breast cancer conference highlights
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... (Edmonton) Thanks to important discoveries in basic and ... cancer has mobilized into a complex offensive spanning ... of Alberta chemistry lab could help find new ... developed a compound that targets a specific enzyme ... activity in cells from brain tumours. , Chemistry ...
    (Date:8/22/2014)... Green tea polyphenols are strong antioxidants and ... protect spinal cord neurons against oxidative stress? ... Affiliated Hospital of Liaoning Medical University, China ... oxidative stress and inhibit neuronal apoptosis, indicating ... in spinal cord neurons under oxidative stress. ...
    (Date:8/22/2014)... birds and the bees. But that old expression ... The fertilization process for flowering plants is particularly ... and female reproductive cells. New research from an ... and including Carnegie,s Wolf Frommer, David Ehrhardt, and ... process that guides flowering plant fertilization. It is ...
    Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Calcium and reproduction go together 2
    ... cancer screening tests are proven to reduce colorectal cancer mortality, ... older receive the recommended tests, according to a report in ... Prevention , a journal of the American Association for Cancer ... conducted a National Health Interview Survey and found only 50 ...
    ... Using an engineered common cold virus, UCLA researchers delivered ... them, using Positron Emission Tomography (PET), to locate the ... the first place prostate cancer goes before invading other ... lymph nodes are very difficult to find using conventional ...
    ... probably one of the most commonly used diagnostics in ... the throat while the patient says, "Aaaah". But, research ... Journal of Medical Engineering and Informatics looks set ... The technique could circumvent the problem of the failing ...
    Cached Biology News:Colorectal cancer screening rates still too low 2UCLA researchers locate and image prostate cancer as it spreads to lymph nodes 2UCLA researchers locate and image prostate cancer as it spreads to lymph nodes 3Sounding out heart problems automatically 2
    (Date:8/22/2014)... August 22, 2014 “Our nation's ... is a national disgrace. Furthermore, every governmental and ... the current, deplorable state of unorganized dysfunction shares ... mistakes," to merely serve as a device to ... of colossal failure(s) that have accumulated through the ...
    (Date:8/21/2014)... 2014 Deep Research Report ... professional and in-depth research report on the ... Seaweed Fertilizer information, including Seaweed Fertilizer definition, ... well as industry overview. This research covers ... as well as global industry analysis covering ...
    (Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... Brazil and ... The uptake of several newly approved agents, the ... this indication and the launch of emerging biologics ... markets. In particular, the emerging IL-5 inhibitors will ...
    (Date:8/21/2014)... August 21, 2014 Pursuit Solutions ... optimization technology and services for Life Sciences sales ... Pharma’s Use of New Commercial Sales Models” by ... Analytics. , The article examines some innovative models ... are being tested in the pharmaceutical market. Robinson ...
    Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
    ... a carbon lattice with a honeycomb structure, has great ... electronic devices. But applications have been stymied because the ... not function effectively as a semiconductor to amplify or ... sheets into nanoscale ribbons can open up a larger ...
    ... , ... ... ... ...
    ... , ... ... ... ...
    Cached Biology Technology:New graphene 'nanomesh' could change the future of electronics 2Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 2Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 3Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 4Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 5Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 6Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 7Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 8Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 9Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 10Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 2Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 3Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 4Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 5Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 6
    Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
    For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
    recombination at attR1 and attR2 sites...
    ...
    Biology Products: